Cargando…

Two-step feature selection for predicting survival time of patients with metastatic castrate resistant prostate cancer

Metastatic castrate resistant prostate cancer (mCRPC) is the major cause of death in prostate cancer patients. Even though some options for treatment of mCRPC have been developed, the most effective therapies remain unclear. Thus finding key patient clinical variables related with mCRPC is an import...

Descripción completa

Detalles Bibliográficos
Autor principal: Shiga, Motoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5130083/
https://www.ncbi.nlm.nih.gov/pubmed/27990267
http://dx.doi.org/10.12688/f1000research.8201.1
_version_ 1782470681815941120
author Shiga, Motoki
author_facet Shiga, Motoki
author_sort Shiga, Motoki
collection PubMed
description Metastatic castrate resistant prostate cancer (mCRPC) is the major cause of death in prostate cancer patients. Even though some options for treatment of mCRPC have been developed, the most effective therapies remain unclear. Thus finding key patient clinical variables related with mCRPC is an important issue for understanding the disease progression mechanism of mCRPC and clinical decision making for these patients. The Prostate Cancer DREAM Challenge is a crowd-based competition to tackle this essential challenge using new large clinical datasets. This paper proposes an effective procedure for predicting global risks and survival times of these patients, aimed at sub-challenge 1a and 1b of the Prostate Cancer DREAM challenge. The procedure implements a two-step feature selection procedure, which first implements sparse feature selection for numerical clinical variables and statistical hypothesis testing of differences between survival curves caused by categorical clinical variables, and then implements a forward feature selection to narrow the list of informative features. Using Cox’s proportional hazards model with these selected features, this method predicted global risk and survival time of patients using a linear model whose input is a median time computed from the hazard model. The challenge results demonstrated that the proposed procedure outperforms the state of the art model by correctly selecting more informative features on both the global risk prediction and the survival time prediction.
format Online
Article
Text
id pubmed-5130083
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher F1000Research
record_format MEDLINE/PubMed
spelling pubmed-51300832016-12-16 Two-step feature selection for predicting survival time of patients with metastatic castrate resistant prostate cancer Shiga, Motoki F1000Res Method Article Metastatic castrate resistant prostate cancer (mCRPC) is the major cause of death in prostate cancer patients. Even though some options for treatment of mCRPC have been developed, the most effective therapies remain unclear. Thus finding key patient clinical variables related with mCRPC is an important issue for understanding the disease progression mechanism of mCRPC and clinical decision making for these patients. The Prostate Cancer DREAM Challenge is a crowd-based competition to tackle this essential challenge using new large clinical datasets. This paper proposes an effective procedure for predicting global risks and survival times of these patients, aimed at sub-challenge 1a and 1b of the Prostate Cancer DREAM challenge. The procedure implements a two-step feature selection procedure, which first implements sparse feature selection for numerical clinical variables and statistical hypothesis testing of differences between survival curves caused by categorical clinical variables, and then implements a forward feature selection to narrow the list of informative features. Using Cox’s proportional hazards model with these selected features, this method predicted global risk and survival time of patients using a linear model whose input is a median time computed from the hazard model. The challenge results demonstrated that the proposed procedure outperforms the state of the art model by correctly selecting more informative features on both the global risk prediction and the survival time prediction. F1000Research 2016-11-16 /pmc/articles/PMC5130083/ /pubmed/27990267 http://dx.doi.org/10.12688/f1000research.8201.1 Text en Copyright: © 2016 Shiga M http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Method Article
Shiga, Motoki
Two-step feature selection for predicting survival time of patients with metastatic castrate resistant prostate cancer
title Two-step feature selection for predicting survival time of patients with metastatic castrate resistant prostate cancer
title_full Two-step feature selection for predicting survival time of patients with metastatic castrate resistant prostate cancer
title_fullStr Two-step feature selection for predicting survival time of patients with metastatic castrate resistant prostate cancer
title_full_unstemmed Two-step feature selection for predicting survival time of patients with metastatic castrate resistant prostate cancer
title_short Two-step feature selection for predicting survival time of patients with metastatic castrate resistant prostate cancer
title_sort two-step feature selection for predicting survival time of patients with metastatic castrate resistant prostate cancer
topic Method Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5130083/
https://www.ncbi.nlm.nih.gov/pubmed/27990267
http://dx.doi.org/10.12688/f1000research.8201.1
work_keys_str_mv AT shigamotoki twostepfeatureselectionforpredictingsurvivaltimeofpatientswithmetastaticcastrateresistantprostatecancer